Quick Answer
Aurinia Pharmaceuticals Inc. reported R&D Expense of $32.51 million for fiscal year 2025.
Aurinia Pharmaceuticals Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $32.51M | +56.4% |
| 2024 | $20.79M | -58.1% |
| 2023 | $49.64M | +10.3% |
| 2022 | $44.99M | -12.0% |
| 2021 | $51.14M | +1.6% |
| 2020 | $50.33M | -4.8% |
| 2019 | $52.87M | +27.8% |
| 2018 | $41.38M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.44M | +176.8% | +13.5% |
| June 30, 2025 | $7.43M | +82.2% | +29.4% |
| March 31, 2025 | $5.74M | +3.5% | +88.5% |
| September 30, 2024 | $3.05M | -77.6% | -25.3% |
| June 30, 2024 | $4.08M | -67.7% | -26.5% |
| March 31, 2024 | $5.55M | -57.8% | -59.2% |
| September 30, 2023 | $13.61M | +24.0% | +7.5% |
| June 30, 2023 | $12.65M | +9.8% | -3.9% |
- Aurinia Pharmaceuticals Inc. showed an increase of +56.4% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Aurinia Pharmaceuticals Inc.’s r&d expense has declined by 21.5% (from $41.38 million to $32.51 million).
- The most recent figure is from Aurinia Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: